You are here

New Robotic Aid for Drugfree Depression Treatment

Non-Invasive Therapy for Patients Who are Nonresponsive to Antidepressants

MagVenture has added the new FDA-approved robotic platform to its clinical system. The TMS-Cobot, will help further elevate the rapidly growing field of neuromodulation, commonly known as Transcranial Magnetic Stimulation (TMS).

Transcranial Magnetic Stimulation (TMS) therapy–– is an effective, non-invasive option for the large number of patients who fail to respond to antidepressants. During treatment, magnetic pulses are applied with a magnetic coil to a certain part of the patient’s brain. This area is the entry-point for treatment as the pulses reach the neural network that controls mood and emotion, potentially alleviating the depression. Patients are fully awake during treatment and can return to their normal activities immediately following the TMS session. Typically, patients will receive a total of 20–30 sessions, one per weekday.

The new robotic TMS-Cobot provides continuous tracking of the patient’s possible head movements during treatment. It also reduces the manual coil-handling time for TMS operators, which is a key factor for clinics that treat many patients.

TMS-Cobot is FDA-indicated for the spatial positioning and orientation of MagVenture’s TMS Therapy system treatment coil.

Source: MagVenture, February 20, 2019

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Old Chemo Drug at High Doses Goads Immune System to Fight Lymphoma